ClinicalTrials.gg
CompletedNCT02725593Updated Feb 23, 2022Results posted

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

A Phase 3 interventional study of Dapagliflozin and Dapagliflozin placebo in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 42 sites in 7 countries. Open to participants aged 10 Years to 24 Years. Per ClinicalTrials.gov, last updated 2022-02-23.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
10 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
95th of 180
72 · median 82
Started
2016
with 18 others
Phase 3
47 of 180
4 open now
Registered
79th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 95th largest by enrollment, is one of 19 that started in 2016, is one of 47 in phase 3, and was the 79th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 10 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.

Read the detailed description

A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients aged 10-24 years

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Diabetes Mellitus
  • Dapagliflozin
  • Placebo
  • Insulin resistance
  • Metabolic Diseases
04

Who can participate

Ages eligible
10 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study-specific procedures
  2. Males and Females, ages 10 years of age, up to but not including 25 years of age at the time of randomization
  3. Previously diagnosed as having type 2 diabetes for at least 2 months by WHO/ADA diagnostic criteria
  4. >= 6.5% and \<= 11% obtained at screening visit
  5. Currently on diet and exercise and a stable dose of metformin (at least 1000 mg daily) for a minimum of 8 weeks, or stable dose of insulin for a minimum of 8 weeks, or a stable combination of metformin (at least 1000 mg daily) and insulin for a minimum of 8 weeks prior to screening
  6. FPG \<=255 mg/dL (\<= 14.2 mmol/L) obtained at screening visit

Exclusion criteria

Exclusion Criteria:

  1. Previous diagnosis of Type 1 diabetes
  2. Diabetes ketoacidosis (DKA) within 6 months of screening
  3. Current use of the following medications for the treatment of diabetes, or use within the specified timeframe prior to screening for the main study:

    • Eight weeks: sulfonylureas, alpha glucosidase inhibitors, metiglinide, or injectable incretins or incretin mimetics or other antidiabetes medications not otherwise specified
    • Sixteen weeks: thiazolidinediones
    • Any previous history or current use of an SGLT2 inhibitor, including dapagliflozin
  4. Initiation or discontinuation of prescription or non-prescription weight loss drugs within 8 weeks of screening.

    Use of prescription or non-prescription weight loss drugs must be stable during the study

  5. Pregnant, positive serum pregnancy test, planning to become pregnant during the clinical trials, or breastfeeding
  6. History of unstable or rapidly progressive renal disease
  7. History of unresolved vesico-ureteral reflux
  8. Replacement or chronic systemic therapy, defined as any dose of systemic corticosteroid taken for > 4 weeks within 3 months prior to the Day 1 visit.

    Note: Topical, nasal, or inhaled corticosteroids are allowed

  9. Abnormal renal function, which is defined in subjects \< 18 years of age as an estimated (eGFR) calculated by the Schwartz Formula \< 80 mL/min/1.73 m2 (1.33 mL/s), and in subjects >= 18 years as an estimated glomerular filtration rate (eGFR) calculated by the MDRD Formula \< 60 mL/min/1.73 m2 (1.33 mL/s)
  10. Presence of either: antibodies to glutamic acid decarboxylase (GAD) or protein tyrosine phosphatase-like protein antibodies (IA-2)
  11. An abnormal TSH value at screening will be further evaluated for free T4. Subjects with abnormal free T4 values will be excluded
  12. Hematuria (confirmed by microscopy at screening) with no explanation as judged by the investigator up to randomization
  13. Anemia of any etiology defined as \<=10.7 g/dL (107 g/L) for females and \<= 11.3 g/dL (113 g/L) for males. Subjects who are considered to have anemia according to local guidelines should be excluded
  14. Volume-depleted subjects. Subjects at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics, should carefully monitor their volume status
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Drug: Dapagliflozin

  • Placebo comparator
    Dapagliflozin placebo

    Drug: Dapagliflozin placebo

Interventions

  • Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.

    Also known as: FORXIGA

  • DrugDapagliflozin placebo

    matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.

06

What researchers measure

Primary outcomes

  1. Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Adjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    Time frame: Baseline to Week 24

  2. Percentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control

    Time frame: Baseline to Week 24

  3. Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24

    Time frame: Baseline to Week 24

07

Results

Posted Dec 2, 2020

Participant flow

Participants took part in the study at 42 study centres in 7 countries worldwide.

Blinded Treatment Period
Participant flow — Blinded Treatment Period
MilestoneDapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mg
Started3933
Received treatment3933
Completed3427
Not completed56
Withdrew: Withdrawal by subject43
Withdrew: Withdrawal by parent/guardian02
Withdrew: Lost to follow-up11
Long Term Extension
Participant flow — Long Term Extension
MilestoneDapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mg
Started3327
Completed3224
Not completed13
Withdrew: Withdrawal by subject13

Outcome measures

PrimaryAdjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24
Time frame:
Baseline to Week 24
Reported as:
Least squares mean · Percentage of HbA1c
Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24
Percentage of HbA1cDapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mg
Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24-0.25 ± 0.300.50 ± 0.34
Statistical analysis
  • Dapagliflozin 10mg/ Dapagliflozin 10mg vs Placebo/ Dapagliflozin 10mg · Mixed model repeated measures analysis · p = 0.101 · Mean difference (final values): -0.75 · 95% CI -1.65 to 0.15
SecondaryAdjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Time frame:
Baseline to Week 24
Reported as:
Least squares mean · mmol/L
Adjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
mmol/LDapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mg
Adjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-0.07 ± 0.530.72 ± 0.61
Statistical analysis
  • Dapagliflozin 10mg/ Dapagliflozin 10mg vs Placebo/ Dapagliflozin 10mg · Mixed model repeated measures analysis · p = 0.340 · Mean difference (final values): -0.78 · 95% CI -2.42 to 0.85
SecondaryPercentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control
Time frame:
Baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control
Percentage of participantsDapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mg
Percentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control5.19.1
Statistical analysis
  • Dapagliflozin 10mg/ Dapagliflozin 10mg vs Placebo/ Dapagliflozin 10mg · Fisher's exact test · p = 0.655 · Mean difference (final values): -3.96 · 95% CI -20.11 to 9.62
SecondaryPercentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24
Time frame:
Baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24
Percentage of participantsDapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mg
Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 2425.04.2
Statistical analysis
  • Dapagliflozin 10mg/ Dapagliflozin 10mg vs Placebo/ Dapagliflozin 10mg · Fisher's exact test · p = 0.056 · Mean difference (final values): 20.83 · 95% CI 0.50 to 41.11

Adverse events

Collected over Up to a maximum of 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin 10mg/ Dapagliflozin 10mg0/39 (0%)2/39 (5.1%)24/39 (61.5%)
Placebo/ Dapagliflozin 10mg0/33 (0%)3/33 (9.1%)19/33 (57.6%)
Most frequent serious events
Most frequent serious events
EventDapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mg
HyperglycaemiaMetabolism and nutrition disorders0/392/33
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/391/33
Abdominal pain lowerGastrointestinal disorders1/390/33
DepressionPsychiatric disorders1/390/33
Most frequent other events
Showing 10 of 27
Most frequent other events
EventDapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mg
NasopharyngitisInfections and infestations5/392/33
Vitamin D deficiencyMetabolism and nutrition disorders5/392/33
HeadacheNervous system disorders5/394/33
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/391/33
HypertriglyceridaemiaMetabolism and nutrition disorders1/393/33
NauseaGastrointestinal disorders3/390/33
Urinary tract infectionInfections and infestations3/391/33
DiarrhoeaGastrointestinal disorders2/392/33
ToothacheGastrointestinal disorders1/392/33
PharyngotonsillitisInfections and infestations0/392/33

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mgTotal
Mean16.1 ± 3.316.2 ± 3.616.1 ± 3.4
Age, Customized
Age, Customized(Participants)Dapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mgTotal
≥10 and ≤15161430
>15 and <18131023
≥18 and <2510919
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mgTotal
Female241943
Male151429
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mgTotal
Hispanic or Latino121224
Not Hispanic or Latino262147
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mgTotal
White281644
Black or African American81018
Asian011
Native Hawaiian or other Pacific Islander101
American Indian or Alaska Native235
Other033
Geographic Region
Geographic Region(Participants)Dapagliflozin 10mg/ Dapagliflozin 10mgPlacebo/ Dapagliflozin 10mgTotal
North America161632
Latin America7916
Europe16824
Asia/Pacific000
08

Study locations

42 sites
  • Research Site
    New Haven, Connecticut 06514-3434, United States
  • Research Site
    Washington, District of Columbia 20010, United States
  • Research Site
    Gainesville, Florida 32610, United States
  • Research Site
    Homestead, Florida 33032, United States
  • Research Site
    Miami, Florida 33015, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Bronx, New York 10467, United States
  • Research Site
    Buffalo, New York 14222, United States
  • Research Site
    Columbus, Ohio 43205, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Memphis, Tennessee 38116, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Lampasas, Texas 76550, United States
  • Research Site
    McAllen, Texas 78503, United States
  • Research Site
    Budapest, 1023, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Beer Sheva, 84101, Israel
  • Research Site
    Haifa, 91096, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Ramat Gan, 5265601, Israel
  • Research Site
    Zerifin, 70300, Israel
  • Research Site
    Culiacan, 80230, Mexico
  • Research Site
    Guadalajara, 44670, Mexico
  • Research Site
    Merida, 97134, Mexico
  • Research Site
    Monterrey, 64460, Mexico
  • Research Site
    México, D.F., 11410, Mexico
  • Research Site
    Zapopan, 45116, Mexico
  • Research Site
    Oradea, 410169, Romania
  • Research Site
    Timisoara, 300011, Romania
  • Research Site
    Izhevsk, 426009, Russian Federation
  • Research Site
    Krasnoyarsk, 660022, Russian Federation
  • Research Site
    Moscow, 117036, Russian Federation
  • Research Site
    Novosibirsk, 630087, Russian Federation
  • Research Site
    Pyatigorsk, 357500, Russian Federation
  • Research Site
    Rostov-on-Don, 344022, Russian Federation
  • Research Site
    Samara, 443079, Russian Federation
  • Research Site
    Saratov, 410054, Russian Federation
  • Research Site
    St. Petersburg, 194100, Russian Federation
  • Research Site
    Tomsk, 634050, Russian Federation
  • Research Site
    Kent, CT9 4AN, United Kingdom
  • Research Site
    Leicester, LE15WW, United Kingdom
09

References and documents

Publications

  • Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022 May;10(5):341-350. doi: 10.1016/S2213-8587(22)00052-3. Epub 2022 Apr 1. PubMed 35378069 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Apr 2020, 45 months.

Results were first posted in Dec 2020, 7 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 45 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2016
First posted
Apr 1, 2016
StartActual
Jun 22, 2016
Primary completionActual
Apr 6, 2020
CompletionActual
Apr 6, 2020
Results first posted
Dec 2, 2020
Last update
Feb 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02725593
Lead sponsor
AstraZeneca
Collaborators
Parexel, Q2 Solutions, PRA Health Sciences, Covance
Responsible party
Sponsor
First posted
Apr 1, 2016
Start date
Jun 22, 2016
Primary completion
Apr 6, 2020
Completion
Apr 6, 2020
Results posted
Dec 2, 2020
Last update
Feb 23, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion